Aprea Therapeutics (NASDAQ:APRE) Given Buy Rating at HC Wainwright
HC Wainwright reissued their buy rating on shares of Aprea Therapeutics (NASDAQ:APRE – Free Report) in a research report sent to investors on Monday, Benzinga reports. They currently have a $20.00 target price on the stock. Separately, Wedbush restated an outperform rating and issued a $11.00 price target on shares of Aprea Therapeutics in a […]
More Stories
Verizon Communications Inc. (NYSE:VZ) Shares Acquired by TrinityPoint Wealth LLC
TrinityPoint Wealth LLC lifted its stake in shares of Verizon Communications Inc. (NYSE:VZ – Free Report) by 3.2% during the...
TrinityPoint Wealth LLC Purchases 75,333 Shares of Invesco BulletShares 2027 Corporate Bond ETF (NASDAQ:BSCR)
TrinityPoint Wealth LLC boosted its position in Invesco BulletShares 2027 Corporate Bond ETF (NASDAQ:BSCR – Free Report) by 75.3% during...
2,465 Shares in Novanta Inc. (NASDAQ:NOVT) Acquired by Chesapeake Capital Corp IL
Chesapeake Capital Corp IL purchased a new position in shares of Novanta Inc. (NASDAQ:NOVT – Free Report) during the third...
Chesapeake Capital Corp IL Takes Position in Applied Digital Co. (NASDAQ:APLD)
Chesapeake Capital Corp IL acquired a new stake in Applied Digital Co. (NASDAQ:APLD – Free Report) during the 3rd quarter,...
Chesapeake Capital Corp IL Has $273,000 Stake in The Greenbrier Companies, Inc. (NYSE:GBX)
Chesapeake Capital Corp IL increased its position in shares of The Greenbrier Companies, Inc. (NYSE:GBX – Free Report) by 27.9%...
Swiss National Bank Sells 8,000 Shares of Marriott International, Inc. (NASDAQ:MAR)
Swiss National Bank decreased its position in shares of Marriott International, Inc. (NASDAQ:MAR – Free Report) by 1.1% in the...